Enrica Marchi MD
Hematologic Oncology
Assistant Professor of Medicine, Microbiology, Immunology and Cancer Biology; Co-Director Program for T-Cell Lymphoma Research; Division of Hematology Oncology; Department of Medicine; University of Virginia
Join to View Full Profile
1240 Lee StCharlottesville, VA 22908
Phone+1 434-924-9333
Fax+1 434-244-7526
Dr. Marchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2015 - 2018
Lincoln Medical and Mental Health CenterResidency, Internal Medicine, 2012 - 2015
New York University School of MedicinePost-Doctoral Fellowship, 2009 - 2011
Columbia University Vagelos College of Physicians and SurgeonsPost-Doctoral Fellowship, 2007 - 2009
University of BolognaClass of 2002
Certifications & Licensure
VA State Medical License 2020 - 2026
NY State Medical License 2015 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Start of enrollment: 2021 Feb 19
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution.Nolan A Wages, Bethany J Horton, Li Liu, Enrica Marchi, Gina R Petroni
Cancers. 2025-03-20 - 1 citationsGlobal outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium.Jessy Xinyi Han, Min Jung Koh, Leora Boussi, Mark Sorial, Sean M McCabe
Blood Advances. 2025-02-11 - A Post-transplant Immunosuppression Complication: Epstein-Barr Virus-Positive Classic Hodgkin Lymphoma Post-transplant Lymphoproliferative Disorder.Himesh B Zaver, Gautham Prakash, Samuel Plant, Jigisha Chaudhari, Jason Erno
ACG Case Reports Journal. 2025-02-01
Press Mentions
UVA Cancer Center Receives $5.75 Million to Battle Rare Blood CancersAugust 4th, 2022
Grant Support
- A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).UNIVERSITY OF VIRGINIA2020–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
